Early Monitoring of Response (MORE) to Golimumab Therapy based on Fecal Calprotectin and Trough Serum Levels in Patients with Ulcerative Colitis: A Multicenter Prospective Observational Study

(1) Verein für Wissenschaft und Fortbildung,Oldenburg,Germany

(2) Bank Vontobel AG,Kassel,Germany

(3) Klinikum Lueneburg,Lueneburg,Germany

(4) Private Practice for Internal Medicine,Lübeck,Germany

(5) Clinical Research Center,Münster,Germany

(6) Kompetenznetz Darmerkrankungen,Kiel,Germany

(7) Private Praxis,Leipzig,Germany

(8) Private Practice,Halle,Germany

(9) Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology,Stuttgart,Germany

(10) DRK Kliniken Berlin I Westend,Berlin,Germany

(11) Universität Kiel UKSH,Kiel,Germany

This item was part of the IBD II (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019